Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes

Modern Pathology

Volumn 23, Issue 7, 2010, Pages 1029-1039

  Moelans, Cathy B ^a   De Weger, Roel A ^a   Monsuur, Hanneke N ^a   Vijzelaar, Raymon ^b   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MRC HOLLAND   (Netherlands)

Author keywords

amplification; breast cancer; copy number; MLPA; oncogenes

Indexed keywords

ADAM PROTEIN; ADAM9 PROTEIN; AURORA A KINASE; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BINDING PROTEIN; CARBOXYPEPTIDASE; CELL CYCLE PROTEIN 6; CYCLIN D1; CYCLIN E1; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR RECEPTOR 1; I KAPPA B KINASE BETA; INDUCIBLE NITRIC OXIDE SYNTHASE; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EMSY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; UNCLASSIFIED DRUG; UVOMORULIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; GENE COPY NUMBER VARIATION; GENE DOSAGE; GENE LOSS; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MITOSIS INDEX; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PATHOLOGY; PHENOTYPE;

BREAST NEOPLASMS; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ONCOGENES; PHENOTYPE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77954242252     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.84     Document Type: Article

References (63)

1. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-69.
2. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-398.
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
5. Hudis CA. Trastuzumab, mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
6. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
7. Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16: 462-469.
8. Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994; 81:137-144.
9. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14: 2702-2708.
10. Tetu B, Brisson J, Plante V, et al. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 1998;11:823-830.
11. Tanner M, Isola J, Wiklund T, et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006;24:2428-2436.
12. Jarvinen TA, Holli K, Kuukasjarvi T, et al. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998;77:2267-2273.
13. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-847.
14. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101:644-650.
15. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8: 1061-1067.
16. Moelans CB, de Weger RA, van Blokland MTM, et al. Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation dependent probe amplification in breast cancer. Mod Pathol 2009; 23:62-70.
17. Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007;39:655-660.
18. Albertson DG. Conflicting evidence on the frequency of ESR1 amplification in breast cancer. Nat Genet 2008;40:821-822.
19. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 2007;38:1105-1122.
20. Elsheikh S, Green AR, Aleskandarany MA, et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2008;109:325-335.
21. Korsching E, Packeisen J, Helms MW, et al. Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immu-nohistochemistry. Br J Cancer 2004;90:1422-1428.
22. Janssen EA, Baak JP, Guervos MA, et al. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 2003;201:555-561.
23. Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleo-tide comparative genomic hybridization array. Clin Cancer Res 2009;15:441-451.
24. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
25. Purnomosari D, Aryandono T, Setiaji K, et al. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer. Biotech Histochem 2006;81:79-85.
26. Moelans CB, de Weger RA, van Blokland MT, et al. HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell Oncol 2009;31:1-10.
27. Moelans CB, de Weger RA, Ezendam C, et al. HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification: influence of manual-and laser microdissection. BMC Cancer 2009;9:4.
28. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004;57:675-681.
29. van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. BMJ 2002;325:648-651.
30. van Diest PJ, Baak JP, Matze-Cok P, et al. Reproduci-bility of mitosis counting in 2469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 1992;23: 603-607.
31. Bunyan DJ, Eccles DM, Sillibourne J, et al. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer 2004;91:1155-1159.
32. Coffa J, van de Wiel MA, Diosdado B, et al. MLPAna-lyzer: data analysis tool for reliable automated normalization of MLPA fragment data. Cell Oncol 2008; 30:323-335.
33. Al-Kuraya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-8540.
34. Cuny M, Kramar A, Courjal F, et al. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 2000;60:1077-1083.
35. Letessier A, Sircoulomb F, Ginestier C, et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 2006;6:245.
36. Blancato J, Singh B, Liu A, et al. Correlation of amplification and overexpression of the c-myc onco-gene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer 2004;90:1612-1619.
37. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-541.
38. Cingoz S, Altungoz O, Canda T, et al. DNA copy number changes detected by comparative genomic hybridization and their association with clinicopatho-logic parameters in breast tumors. Cancer Genet Cytogenet 2003;145:108-114.
39. Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006;13:39-49.
40. Kwek SS, Roy R, Zhou H, et al. Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 2009; 28:1892-1903.
41. Loo LW, Grove DI, Williams EM, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004; 64:8541-8549.
42. Fridlyand J, Snijders AM, Ylstra B, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006;6:96.
43. Nishikawa N, Toyota M, Suzuki H, et al. Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res 2007;67:9649-9657.
44. Kim C, Bryant J, Horne Z, et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo [abstract]. Breast Cancer Res Treat 2005;94(Suppl 1):S6. Abstract 46.
45. Potemski P, Kusinska R, Watala C, et al. Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. J Exp Clin Cancer Res 2006;25: 59-64.
46. Callagy G, Pharoah P, Chin SF, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005;205:388-396.
47. Kirkegaard T, Nielsen KV, Jensen LB, et al. Genetic alterations of CCND1 and EMSY in breast cancers. Histopathology 2008;52:698-705.
48. Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115:523-535.
49. van Diest PJ, Michalides RJ, Jannink L, et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 1997;150:705-711.
50. Park K, Han S, Shin E, et al. EGFR gene and protein expression in breast cancers. Eur J Surg Oncol 2007;33:956-960.
51. Rodriguez-Pinilla SM, Jones RL, Lambros MB, et al. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol 2007;60: 1017-1023.
52. Cleton-Jansen AM. E-cadherin and loss of heterozyg-osity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 2002;4:5-8.
53. Camilleri-Broet S, Cremer I, Marmey B, et al. TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 2007;26:142-147.
54. Grunewald TG, Butt E. The LIM and SH3 domain protein family: structural proteins or signal transducers or both? Mol Cancer 2008;7:31.
55. Zhu Y, Qi C, Jain S, et al. Amplification and over-expression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci USA 1999;96:10848-10853.
56. Arriola E, Marchio C, Tan DS, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008;88:491-503.
57. Jensen LB, Bartlett JM, Witton CJ, et al. Frequent amplifications and deletions of G1/S-phase transition genes, CCND1 and MYC in early breast cancers: a potential role in G1/S escape. Cancer Biomark 2009; 5:41-49.
58. Ginestier C, Cervera N, Finetti P, et al. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 2006;12:4533-4544. (Pubitemid 44297802)
59. Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997;14:2195-2200.
60. Elbauomy ES, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9:R23.
61. Chalmers IJ, Aubele M, Hartmann E, et al. Mapping the chromosome 16 cadherin gene cluster to a minimal deleted region in ductal breast cancer. Cancer Genet Cytogenet 2001;126:39-44.
62. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23:7483-7490.
63. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophospha-mide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-1116.